Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS42001667EBVENSG00000254087.8protein_codingLYNYesNo4067P07948
Q6NUK7
TVIS10010490HBVENSG00000254087.8protein_codingLYNYesNo4067P07948
Q6NUK7
TVIS10011203HBVENSG00000254087.8protein_codingLYNYesNo4067P07948
Q6NUK7
TVIS10011382HBVENSG00000254087.8protein_codingLYNYesNo4067P07948
Q6NUK7
TVIS10001563HBVENSG00000254087.8protein_codingLYNYesNo4067P07948
Q6NUK7
TVIS10023744HBVENSG00000254087.8protein_codingLYNYesNo4067P07948
Q6NUK7
TVIS10031166HBVENSG00000254087.8protein_codingLYNYesNo4067P07948
Q6NUK7
TVIS10049248HBVENSG00000254087.8protein_codingLYNYesNo4067P07948
Q6NUK7
TVIS30068958HIVENSG00000254087.8protein_codingLYNYesNo4067P07948
Q6NUK7
TVIS20007634HPVENSG00000254087.8protein_codingLYNYesNo4067P07948
Q6NUK7
TCGA Plot Options
Drug Information
GeneLYN
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0004315
UniProt IDP07948
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830